Moustafa Abdou: New Horizons in Hematology and Recent Drug Approvals
Moustafa Abdou, Author and Founder of AskHematologist.com, shared a post on LinkedIn:
“New Horizons in Hematology: A Review of Recent Drug Approvals
Recent advances in hematology are rapidly transforming the management of both malignant and non-malignant blood disorders.
From gene therapy and non-factor treatments in hemophilia to targeted therapies such as JAK inhibitors and antibody–drug conjugates in hematologic malignancies, modern therapeutics are increasingly driven by precision medicine and molecular targeting.
Agents such as brentuximab vedotin have redefined lymphoma treatment, while ruxolitinib has significantly improved outcomes in myeloproliferative neoplasms.
In resistant leukemias, novel agents like omacetaxine offer alternative mechanisms to overcome treatment resistance.
Equally important are advances in supportive care.
G-CSF therapies, iron chelation, direct oral anticoagulants, and enzyme replacement therapies have reduced complications and improved quality of life across a wide range of hematologic conditions.
These developments highlight a comprehensive shift toward more effective, personalised, and safer treatment strategies in hematology.”
Stay updated with Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients